GMAB

50.6001.46%
JG

Jan G.J. van de Winkel

Co-Founder, President & CEO

Dr. Jan G.J. van de Winkel, Ph.D. was Independent Director of HOOKIPA Pharma Inc. from 2023 until August 30, 2024 and served as Chairman of the Board since 2024 August 30, 2024. Dr. Winkel served as a Member of Advisory board at Thuja Capital Management B.V. Dr. van de Winkel served as a Member of Scientific Advisory Board. Dr. Winkel was Director of LEO Pharma A/S from April 06, 2017 until August 2024. Dr. Winkel joined the LEO Pharma A/S on April 06, 2017. Dr. Winkel is Co-Founder, President & CEO of Genmab A/S. Dr. Winkel joined the Genmab A/S in June 1998. Dr. van de Winkel has years of experience in the therapeutic antibody field and served as Vice President and Scientific 154 Table of Contents Director of Medarex Europe prior to joining Genmab. Dr. Winkel is Chairman of Hookipa Biotech AG. Dr. Winkel was Independent Chairman of the Board of HOOKIPA Pharma Inc. from 2017 until 2023. Dr. Winkel is Independent Director of Omega Alpha SPAC from January 2021. Dr. Winkel was Member of Life Sciences Advisory Board of Advent Venture Partners. Dr. Winkel focused on Life Sciences. Dr. Winkel was Director of Forward Pharma A/S until May 03, 2017. Dr. Winkel was employed at Forward Pharma A/S from August 12, 2014 to May 03, 2017. Dr. Winkel was Member of Scientific Advisory Board of Biotechnology Turnaround Fund B.V. Dr. Winkel was Advisor of Aglaia Oncology Fund. Dr. Winkel has Ph.D. in Immunology from Radboud University of Nijmegen in 1988, M.S. in Biology from Radboud University of Nijmegen in 1985.

Positions